On June 1, 2017 Ipsen reported that lanreotide (Somatuline Autogel Depot), cabozantinib (Cabometyx), irinotecan liposome injection (Onivyde) and the investigational compounds 177Lu-OPS201 and 68Ga-OPS201 are the subject of presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2017 conference (Press release, Ipsen, JUN 1, 2017, View Source [SID1234519340]). The meeting takes place in Chicago, Illinois, June 2-6, 2017. Schedule your 30 min Free 1stOncology Demo! "Ipsen continues to build on the strength of its Oncology portfolio at ASCO (Free ASCO Whitepaper) this year with new data being presented to support our key products as well as our early-stage radiopharmaceutical compounds,", said David Meek, Chief Executive Officer, Ipsen. "We are establishing a leadership position in several specialty Oncology markets and will continue to collaborate with the research community to accelerate the discovery and development of therapeutic options with the goal of improving the lives of people living with cancer."
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These studies demonstrate Ipsen’s steadfast commitment to cancer patients for whom innovative options are urgently needed," said Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen. "Researchers are sharing deeper insights from Ipsen’s oncology’s portfolio to continue to improve treatment of gastroenteropancreatic neuroendocrine tumors, advanced pancreatic cancer and advanced renal cell carcinoma."